Monopar's ALXN1840 Gets FDA's Rare Pediatric Disease Designation For Wilson Disease

Monopar Therapeutics (MNPR) said the FDA granted Rare Pediatric Disease designation to ALXN1840 for Wilson disease. While this is a positive regulatory milestone, it is not yet clinical efficacy or approval, so near-term market impact is likely modest.

Analysis

Monopar Therapeutics (MNPR) said the FDA granted Rare Pediatric Disease designation to ALXN1840 for Wilson disease. While this is a positive regulatory milestone, it is not yet clinical efficacy or approval, so near-term market impact is likely modest.